Cellerys
Zurich, Switzerland· Est.
Cellerys develops antigen-specific immunotherapies for autoimmune diseases using T-cell tolerance induction technology.
Private Company
Total funding raised: $31.5M
About
Cellerys develops antigen-specific immunotherapies for autoimmune diseases using T-cell tolerance induction technology.
Cell & Gene Therapy
Funding History
4Total raised:$31.5M
Series A$15M
Series A$8.5M
Seed$5.5M
Seed$2.5M